Welcome to our dedicated page for Absci SEC filings (Ticker: ABSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Absci Corporation (Nasdaq: ABSI) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical and biotechnology company using generative AI and synthetic biology to design biologic therapeutics, Absci uses these filings to report on its financial condition, pipeline progress, capital markets activity, and key corporate events.
Investors can review Absci’s current reports on Form 8-K, which have recently covered topics such as quarterly financial results, updates on internal programs like ABS-201 and ABS-101, investor presentations, and material definitive agreements including underwritten equity offerings. These filings also confirm that Absci’s common stock is listed on The Nasdaq Global Select Market under the symbol ABSI.
In addition to 8-Ks, users can locate Absci’s annual reports on Form 10-K and quarterly reports on Form 10-Q through this page. Those reports typically include management’s discussion and analysis, audited or reviewed financial statements, and detailed information on the company’s Integrated Drug Creation platform, clinical-stage programs, risk factors, and liquidity. For a company like Absci, these periodic reports are central to understanding how it funds and advances its AI-designed antibody pipeline and partnered drug creation projects.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify items such as changes in cash runway, updates to clinical development plans, or new collaboration agreements. Real-time updates from the SEC’s EDGAR system ensure that new Absci filings appear promptly, while access to insider transaction reports on Form 4, when filed, can help users monitor equity awards and trades by directors and officers.
By using this page, investors and researchers can efficiently navigate Absci’s regulatory history, compare successive filings, and place news releases about its generative AI platform and clinical programs in the context of the company’s formal SEC disclosures.
Absci Corporation updated its governance and leadership structure. The board approved amended and restated indemnification agreements for all current directors and officers, adding more detailed change-in-control definitions, a presumption of good faith for officer indemnitees, coverage for separate counsel after a change in control, and an exclusion for incentive- and equity-based compensation subject to Rule 10D-1 clawbacks.
Chief Innovation Officer Andreas Busch, Ph.D. will retire effective March 31, 2026, then serve as a scientific advisor for two years starting April 3, 2026. Under an Advisor Agreement, he will receive a $25,500 annual cash retainer and equity awards of stock options for 22,800 shares and 5,800 restricted stock units. The company extended the exercise period on 2,489,290 vested stock options he holds, generally until three months after his advisory service ends or their original expiration, with specific provisions for cause, death, or disability; all unvested options at retirement will lapse.
Absci also announced the appointment of Ransi Somaratne, M.D., a veteran clinical development leader, as Chief Medical Officer to lead clinical strategy for its AI-designed therapeutics pipeline, including the ABS-201 program.
Pangalos Menelas N reported acquisition or exercise transactions in this Form 4 filing.
Absci Corp director Menelas N. Pangalos reported equity awards tied to his role on the company’s scientific advisory board. He received stock options for 22,800 shares and a grant of 5,800 Restricted Stock Units (RSUs), both at no cash cost per share.
The RSUs are scheduled to vest and settle over one year beginning on January 1, 2026, in substantially equal monthly installments, conditioned on his continuous service. The stock options follow the same one-year, monthly vesting schedule starting on that date. Following the RSU grant, his directly held common stock position is 194,855 shares.
Absci Corp Chief Legal Officer Shelby J. Walker reported equity awards and a related tax-withholding share disposition. On March 2, Walker received a grant of 90,300 shares of common stock as restricted stock units under Absci’s 2021 Stock Option and Incentive Plan, and a separate stock option covering 356,300 shares at an exercise price of $0.00 per share.
The RSUs and the option are scheduled to vest in three substantially equal annual installments beginning on March 1, 2027, subject to continued service. On March 3, 9,825 shares of common stock at $2.80 per share were withheld by Absci to cover tax obligations tied to RSU vesting, which the filing states was not a discretionary trade. After these transactions, Walker directly owned 139,775 shares of common stock.
Absci Corp Chief Executive Officer Sean McClain reported equity compensation and related tax withholding transactions. On March 2, 2026, he received 406,200 shares of common stock as a restricted stock unit award and a stock option for 1,603,200 shares at an exercise price of $0.00 per share, both vesting in three equal annual installments starting March 1, 2027, subject to continued service. On March 3, 2026, 25,316 shares of common stock were withheld at $2.80 per share to cover tax obligations from RSU vesting, which the filing states was not a discretionary trade.
Absci Corp executive Todd Bedrick reported equity compensation changes. He received 49,600 shares of common stock as restricted stock units and a stock option for 195,900 shares, while 5,282 shares were withheld at about $2.80 per share to cover tax on vesting rather than from a discretionary sale.
Absci Corp CFO/CBO Zachariah Jonasson reported multiple equity compensation transactions. He received a grant of 135,400 shares of common stock in the form of restricted stock units under the 2021 Stock Option and Incentive Plan and a stock option covering 534,400 shares.
The RSUs and the option vest in three substantially equal annual installments starting on March 1, 2027, conditional on his continued service. A separate disposition of 10,848 common shares at $2.80 per share reflects shares withheld by Absci to cover tax obligations on RSU vesting and is not a discretionary trade. Following these events, he directly holds 499,783 common shares.
Absci Corp Chief Innovation Officer Andreas Busch reported a tax-related share disposition in a Form 4. On March 3, 2026, 1,257 shares of common stock at $2.80 per share were withheld by Absci to cover tax obligations from vesting restricted stock units. This reduced his directly held stake to 321,446 shares. According to the footnote, this was not a discretionary trade but an automatic tax-withholding transaction.
Absci Corp executive reports tax-related share withholding
Absci Corp CFO/CBO Zachariah Jonasson reported a disposition of 8,307 shares of common stock at $2.74 per share. The shares were withheld by the company to cover tax obligations from vesting restricted stock units, not from a discretionary trade. After this, he directly owns 375,231 shares.
Absci Corp executive Zachariah Jonasson, the company’s CFO and CBO, reported a tax-related share disposition. On this Form 4/A, 17,496 shares of common stock were withheld by Absci at a price of $2.99 per share to satisfy tax obligations tied to vesting restricted stock units. After this withholding transaction, Jonasson directly owned 383,538 common shares. The footnote explains that this was not a discretionary trade by Jonasson but an automatic share withholding to cover taxes.
Absci Corp Chief Executive Officer Sean McClain reported a tax-related share disposition connected to vesting restricted stock units. The company withheld 26,761 shares of common stock at a price of $2.99 per share to satisfy withholding obligations, and McClain held 8,334,567 shares directly afterward. The filing specifies this was a tax-withholding event, not a discretionary trade.